(MNMD) Mind Medicine - Ratings and Ratios
Phase 3 Anxiety, Phase 1 Autism
Description: MNMD Mind Medicine
Mind Medicine Inc. is a clinical-stage biopharmaceutical company pioneering novel treatments for brain health disorders, with a focus on developing innovative therapies for mental health conditions. The companys lead candidates, MM120 and MM402, are progressing through clinical trials, targeting generalized anxiety disorder, attention deficit hyperactivity disorder, and autism spectrum disorder.
The companys MM120 is in Phase 3 trials for generalized anxiety disorder and attention deficit hyperactivity disorder, indicating a significant potential for near-term breakthroughs. Meanwhile, MM402, a proprietary R-enantiomer of 3,4-methylenedioxymethamphetamine, is in Phase 1 trials for treating core symptoms of autism spectrum disorder, showcasing the companys diverse pipeline.
With a market capitalization of $506.96 million, Mind Medicine Inc. is positioned within the biotechnology sector, a space known for high-risk, high-reward investments. The absence of a price-to-earnings ratio reflects the companys current stage of development, as it is not yet profitable. The return on equity stands at -33.44%, underscoring the significant investment in research and development.
Analyzing the technical data, the stocks last price is $6.74, with short-term, mid-term, and long-term simple moving averages at $7.28, $6.80, and $6.81, respectively. The average true range indicates a volatility of 7.23%. Given the current SMA20 above the last price, a potential short-term trend reversal or consolidation may be anticipated. Considering the companys progression through clinical trials and the potential impact on stock price, a forecast can be made.
Based on the fundamental and technical data, a potential price target for MNMD could be forecasted by analyzing the historical volatility and the potential catalysts such as clinical trial results. If MM120 successfully completes Phase 3 trials, it could lead to a significant increase in stock price, potentially pushing it towards the 52-week high of $9.89. Conversely, failure could result in a decline towards the 52-week low of $4.89. A more conservative estimate, considering the current SMA50 and SMA200, might place a near-term target between $6.80 and $7.28, with potential for breakout or breakdown depending on clinical trial outcomes and broader market conditions.
MNMD Stock Overview
| Market Cap in USD | 718m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2020-03-03 |
MNMD Stock Ratings
| Growth Rating | 25.1% |
| Fundamental | 20.0% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 26.3% |
| Analyst Rating | 4.64 of 5 |
MNMD Dividends
Currently no dividends paidMNMD Growth Ratios
| Growth Correlation 3m | 68.5% |
| Growth Correlation 12m | 52.4% |
| Growth Correlation 5y | -57.2% |
| CAGR 5y | 8.96% |
| CAGR/Max DD 3y | 0.13 |
| CAGR/Mean DD 3y | 0.20 |
| Sharpe Ratio 12m | -0.06 |
| Alpha | 41.29 |
| Beta | 0.845 |
| Volatility | 67.26% |
| Current Volume | 761.8k |
| Average Volume 20d | 960.8k |
| Stop Loss | 8.9 (-6.8%) |
| Signal | -0.36 |
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income (-114.5m TTM) > 0 and > 6% of Revenue (6% = -6.84m TTM) |
| FCFTA -0.30 (>2.0%) and ΔFCFTA -5.85pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -132.6% (prev 4255 %; Δ -4387 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.38 (>3.0%) and CFO -101.6m > Net Income -114.5m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 4.98 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (85.3m) change vs 12m ago 18.68% (target <= -2.0% for YES) |
| Gross Margin 100.5% (prev 56.24%; Δ 44.22pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover -42.75% (prev 1.80%; Δ -44.56pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -13.24 (EBITDA TTM -47.0m / Interest Expense TTM 4.32m) >= 6 (WARN >= 3) |
Altman Z'' -9.54
| (A) 0.57 = (Total Current Assets 189.1m - Total Current Liabilities 38.0m) / Total Assets 265.1m |
| (B) -1.75 = Retained Earnings (Balance) -465.0m / Total Assets 265.1m |
| warn (B) unusual magnitude: -1.75 — check mapping/units |
| (C) -0.21 = EBIT TTM -57.3m / Avg Total Assets 266.6m |
| (D) -5.82 = Book Value of Equity -464.2m / Total Liabilities 79.7m |
| Total Rating: -9.54 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 19.97
| 1. Piotroski 2.50pt = -2.50 |
| 2. FCF Yield -12.88% = -5.0 |
| 3. FCF Margin -69.42% = -7.50 |
| 4. Debt/Equity 0.43 = 2.41 |
| 5. Debt/Ebitda -1.68 = -2.50 |
| 6. ROIC - WACC -30.88% = -12.50 |
| 7. RoE -50.24% = -2.50 |
| 8. Rev. Trend -4.37% = -0.22 |
| 9. Rev. CAGR 0.0% = 0.0 |
| 10. EPS Trend 11.02% = 0.28 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of MNMD shares?
Over the past week, the price has changed by +1.70%, over one month by -0.62%, over three months by +33.75% and over the past year by +50.16%.
Is Mind Medicine a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of MNMD is around 9.54 USD . This means that MNMD is currently overvalued and has a potential downside of -0.1%.
Is MNMD a buy, sell or hold?
- Strong Buy: 7
- Buy: 4
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the MNMD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 25 | 161.8% |
| Analysts Target Price | 25 | 161.8% |
| ValueRay Target Price | 10.6 | 11.3% |
Last update: 2025-09-15 04:40
MNMD Fundamental Data Overview
CCE Cash And Equivalents = 183.0m USD (Cash And Short Term Investments, last quarter)
Revenue TTM is 0, using Net Income TTM -114.5m + Cost of Revenue 527.0k = -114.0m USD
P/B = 3.8742
Beta = 2.966
Revenue TTM = -114.0m USD
EBIT TTM = -57.3m USD
EBITDA TTM = -47.0m USD
Long Term Debt = 41.2m USD (from longTermDebt, last quarter)
Short Term Debt = 38.0m USD (from totalCurrentLiabilities, last quarter)
Debt = 79.1m USD (Calculated: Short Term 38.0m + Long Term 41.2m)
Net Debt = 7.80m USD (from netDebt column, last quarter)
Enterprise Value = 614.4m USD (718.3m + Debt 79.1m - CCE 183.0m)
Interest Coverage Ratio = -13.24 (Ebit TTM -57.3m / Interest Expense TTM 4.32m)
FCF Yield = -12.88% (FCF TTM -79.1m / Enterprise Value 614.4m)
FCF Margin = -69.42% (FCF TTM -79.1m / Revenue TTM -114.0m)
Net Margin = -100.5% (Net Income TTM -114.5m / Revenue TTM -114.0m)
Gross Margin = -100.5% ((Revenue TTM -114.0m - Cost of Revenue TTM 527.0k) / Revenue TTM)
Tobins Q-Ratio = -1.32 (set to none) (Enterprise Value 614.4m / Book Value Of Equity -464.2m)
Interest Expense / Debt = 2.95% (Interest Expense 2.34m / Debt 79.1m)
Taxrate = 21.0% (US default)
NOPAT = -57.3m (EBIT -57.3m, no tax applied on loss)
Current Ratio = 4.98 (Total Current Assets 189.1m / Total Current Liabilities 38.0m)
Debt / Equity = 0.43 (Debt 79.1m / last Quarter total Stockholder Equity 185.4m)
Debt / EBITDA = -1.68 (Net Debt 7.80m / EBITDA -47.0m)
Debt / FCF = -1.00 (Debt 79.1m / FCF TTM -79.1m)
Total Stockholder Equity = 228.0m (last 4 quarters mean)
RoA = -43.20% (Net Income -114.5m, Total Assets 265.1m )
RoE = -50.24% (Net Income TTM -114.5m / Total Stockholder Equity 228.0m)
RoCE = -21.27% (Ebit -57.3m / (Equity 228.0m + L.T.Debt 41.2m))
RoIC = -22.43% (NOPAT -57.3m / Invested Capital 255.3m)
WACC = 8.46% (E(718.3m)/V(797.4m) * Re(9.13%)) + (D(79.1m)/V(797.4m) * Rd(2.95%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 96.97 | Cagr: 10.21%
Discount Rate = 9.13% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -79.1m)
EPS Correlation: 11.02 | EPS CAGR: 0.0% | SUE: -0.49 | # QB: False
Revenue Correlation: -4.37 | Revenue CAGR: 0.0%
Additional Sources for MNMD Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle